Biomerica Inc. reported its financial results for the second quarter of fiscal 2026, ending November 30, 2025. The company posted revenue of USD 2.96 million for the quarter. Net loss for the same period was USD 1.32 million. For the six months ended November 30, 2025, revenue reached USD 6.05 million and net loss was USD 1.31 million. Operating expenses decreased by 4% year-to-date, and research and development expenses were reduced by 27%. The company’s cash position increased to USD 2.5 million, and working capital improved by 14.7% year-to-date. Biomerica Inc. continues to emphasize cost discipline and operational efficiency, while investing in the commercial launch of new diagnostic products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomerica Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9625817) on January 14, 2026, and is solely responsible for the information contained therein.